Pharma Industry News Update: 30 May 2017

The Digital Gap Between Pharma and Other Industries In this 2-minute audio snippet, Brain Fox, Senior Partner at McKinsey, talks about how the pharma industry lags other industries in its investment in digital technology and in testing the effectiveness of its digital marketing campaigns.

FDA Sets a Higher Pace for Drug Approvals

Most Are Targeted to Smaller Patient Populations

[From] The number of new drugs approved for sale in United States and Europe has bounced back this year [so far], suggesting a marked slowdown in 2016 was an aberration rather than a sign of flagging research and development productivity.

The U.S. Food and Drug Administration has already cleared 21 new prescription medicines for sale against 22 in the whole of 2016 (read New Drugs Approved by FDA in 2016 is Half the Number Approved in 2015), and just nine at this stage last year.

Hilary Thomas, chief medical adviser at KPMG, said U.S. regulators in particular were showing an innovative approach that was helping to accelerate approvals. Still, the targeted nature of many new medicines will limit the overall patient population getting the latest wave of novel drugs.

“What the data masks is that while there might be more approvals, the total number of people getting new drugs is probably not going to up hugely because these are more specific, personalized treatments,” Thomas said.

More here…

Patient Engagement Solutions Summit

Engaging patients in their healthcare and getting them to comply with adhering to their medication plan has always been a hot button issue. On June 22-23, experts in the field will present their successes, novel processes and advancements for engaging patients and infusing insights back into the business at the Patient Engagement Solutions Summit.

Brian Lynch, Senior Director of Innovation at West Pharmaceutical Services offers a preview into what’s to come. How is he directly involved in patient activation? What role does his team play? How is his organization patient-centric? Read on here to find out.

View Q&A Register Now Download Brochure

We hope you can join us for this opportunity to benchmark with your peers on lessons learned and experiences to date, and take away key action items on how to enhance the patient experience.

For more information, please download the agenda or visit PharmaMarketingNews readers can save $400 off of the standard rate by using code ZDD492 to register.*

See you there!

CBI | 800-817-8601 |

*Cannot be combined with other offers or used towards a current registration. Other restrictions may apply.

sponsored by CBI

Facebook’s Invite-Only Pharma Summit

You’re Probably Not on the List 🙁

[From] Facebook is hosting an invitation-only summit dedicated to health on June 6 in New York, according to a source familiar with the matter. 

It’s part of an initiative for advertisers called “Facebook Health,” run by a small team reporting into former Google director Meredith Guerriero.

The June 6 meeting is primarily geared to marketers in the pharmaceutical industry, although other health industry leaders might also be in attendance. Facebook Health [is said] to unveil tweaks to the ad product, so pharma companies can more easily plug themselves on the platform.

In November, the company made its first appearance at a conference to show off its scrolling ISI feature to pharma executives. That feature allows drug companies to remain inside Facebook’s limits for text and photo copy but incorporate required safety information. After the rollout, Bayer launched its first Facebook ad campaign for a multiple sclerosis drug and injector (read Bayer’s Betaseron Facebook Ad Uses a New Feature: Scrolling ISI).

More here…

Further Reading: